STAR SPORTS MED (01609) repurchased 8,000 shares on October 27 for approximately HK$430,100.
STAR SPORTS MED (01609) announced that on October 27, 2026, the company repurchased 8,000 shares for approximately HK$430,100, at a repurchase price of HK$52.95 to HK$55.8 per share.
STAR SPORTS MED (01609) announced that on October 27, 2026, the company repurchased 8,000 shares for approximately HK$430,100, at a repurchase price of HK$52.95 to HK$55.8 per share.
Related Articles
CSPC PHARMA (01093): Results from the Phase I/II Clinical Study of SYS6043 (B7-H3 ADC) for the Treatment of Advanced Breast Cancer Presented as a Rapid Oral Presentation at the 2026 ESMO Congress
CSPC PHARMA (01093): Results of the Phase I/II Clinical Study of the Anti-PD-1/IL-15 Bifunctional Fusion Protein SYS6090 (JMT108) as Monotherapy for Advanced Solid Tumors Presented as a Rapid Oral Presentation at the 2026 ESMO Congress
GLOBAL NEW MAT (06616): Chen Xi Appointed as Joint Company Secretary
CSPC PHARMA (01093): Results from the Phase I/II Clinical Study of SYS6043 (B7-H3 ADC) for the Treatment of Advanced Breast Cancer Presented as a Rapid Oral Presentation at the 2026 ESMO Congress
CSPC PHARMA (01093): Results of the Phase I/II Clinical Study of the Anti-PD-1/IL-15 Bifunctional Fusion Protein SYS6090 (JMT108) as Monotherapy for Advanced Solid Tumors Presented as a Rapid Oral Presentation at the 2026 ESMO Congress
GLOBAL NEW MAT (06616): Chen Xi Appointed as Joint Company Secretary
